Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 5;71(8):2002-2005.
doi: 10.1093/cid/ciaa473.

Xpert MTB/RIF Ultra for the Diagnosis of Tuberculous Meningitis: A Small Step Forward

Joseph Donovan  1   2 , Fiona V Cresswell  3   4   5 , Nguyen Thuy Thuong Thuong  1   2 , David R Boulware  6 , Guy E Thwaites  1   2 , Nathan C Bahr  7 ; Tuberculous Meningitis International Research Consortium
Collaborators, Affiliations

Xpert MTB/RIF Ultra for the Diagnosis of Tuberculous Meningitis: A Small Step Forward

Joseph Donovan et al. Clin Infect Dis. .

Abstract

The delayed diagnosis of tuberculous meningitis (TBM) leads to poor outcomes, yet the current diagnostic methods for identifying Mycobacterium tuberculosis in cerebrospinal fluid (CSF) are inadequate. The first comparative study of the new GeneXpert MTB/RIF Ultra (Xpert Ultra) for TBM diagnosis suggested increased sensitivity of Xpert Ultra. Two subsequent studies have shown Xpert Ultra has improved sensitivity, but has insufficient negative predictive value to exclude TBM. Collecting and processing large volumes of CSF for mycobacterial testing are important for optimal diagnostic test performance. But clinical, radiological, and laboratory parameters remain essential for TBM diagnosis and empiric therapy is often needed. We therefore caution against the use of Xpert Ultra as a single diagnostic test for TBM; it cannot be used to "rule out" TBM.

Keywords: Ultra; Xpert; cerebrospinal fluid; diagnosis; tuberculous meningitis.

PubMed Disclaimer

References

    1. Christensen A-SH, Roed C, Omland LH, Andersen PH, Obel N, Andersen ÅB. Long-term mortality in patients with tuberculous meningitis: a Danish nationwide cohort study. PLoS One 2011; 6:e27900 Available at: http://www.ncbi.nlm.nih.gov/pubmed/22132165. Accessed 10 February 2020. - PMC - PubMed
    1. Vinnard C, King L, Munsiff S, et al. Long-term mortality of patients with tuberculous meningitis in New York City: a cohort study. Clin Infect Dis 2016; 64:ciw763 Available at: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciw763. Accessed 10 February 2020. - DOI - PMC - PubMed
    1. Thwaites GE, Bang ND, Dung NH, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351:1741–1751. Available at: http://www.nejm.org/doi/abs/10.1056/NEJMoa040573. Accessed 4 May 2018. - DOI - PubMed
    1. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13:27–35. Available at: http://linkinghub.elsevier.com/retrieve/pii/S1473309912702645. Accessed 12 August 2018. - PubMed
    1. He Y, Han C, Chang K-F, Wang M-S, Huang T-R. Total delay in treatment among tuberculous meningitis patients in China: a retrospective cohort study. BMC Infect Dis 2017; 17:341 Available at: http://www.ncbi.nlm.nih.gov/pubmed/28499348. Accessed 7 January 2019. - PMC - PubMed

Publication types

MeSH terms